To read this content, please activate your Sanofi Campus account via the email we've sent to you.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

title

In order to see relevant content, tell us what you are interested in

Title

Quick Summary

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

complete your profile to help us provide you with content that's relevant to you.

Your profile is incomplete

Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.

The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.

Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.

Enjoy more exclusive content{newline}by <a>registering today</a>

MAT-XU-2300297 (v3.0) - Date of preparation: October 2023

MAT-XU-2305062 (v1.0) - Date of preparation: November 2023

MAT-XU-2300297 (v3.0) Date of Preparation: October 2023

MAT-XU-2305047 (v1.0) - Date of preparation: November 2023

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

Share via {platform} (opens email client)

Cause And Symptoms

Complications

Diagnosis And Treatment

Overview

Prevention

References

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

The page you are looking for may be under maintenance, or the link may be incorrect.

Sorry, we can't find this page

There are no upcoming events

Showing {start}–{end} of {total} events

Event details

Check back later for upcoming events, or browse all available events across therapeutic areas.

There are no events scheduled for this therapeutic area

Something went wrong

Try a different keyword, date range, or venue.

No matching events

Registration information

Success! We've received your request

You are going to a website that is not operated by Sanofi or a Sanofi website where the terms of use may differ. For external websites, Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party or Sanofi sites.

You are about to leave Sanofi campus website.

You are about to leave Campus.sanofi/uk.

Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

Title should not exceed 100 characters

Enter your title

This site is intended for UK healthcare professionals only and contains information on Sanofi UK's medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a UK healthcare professional. This site contains promotional information. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

MAT-XU-2300297 (v7.0) - Date of Preparation: July 2025

Welcome to Sanofi Campus UK

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Review the materials in your cart before checkout.

Browse and order materials for your practice.

Filters

Materials

Cart

Checkout

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privary matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My Consent

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please sign in to access to the results

You need to sign-in to your account in order to access medical content.

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

You are entering to Sanofi Content Site

You are about to leave the T1D website

Welcome to the T1D Sanofi Website

Therapeutic Areas

<a href="${link:{uuid:{2a02177b-5764-4cb8-98b6-34b9445e0571},repository:{dam},path:{/Portal/UK/Prescribing-Information/Toujeo-PI-UK.pdf}}}">Toujeo (insulin glargine 300U/mL) Prescribing Information</a>

<h2 style="text-align:center;">A Century of Insulin Experience</h2>

For over 100 years, Sanofi has been committed to the development and production of insulin therapies for people living with diabetes1. Our long-standing heritage in diabetes care has enabled us to build extensive expertise in insulin manufacturing and supply chain management.

GENERAL-MEDICINES

DIABETES-CORE

OTHER-DIABETES-TOPICS

TYPE-2-DIABETES

TYPE-1-DIABETES

DIABETES

Learn more about Toujeo®

<h2 style="text-align:center;">Evaluating the Environmental Impact Across the Pen Manufacturing Chain</h2>
Toujeo®(insulin glargine U300) pens have been developed with a strong focus on environmental sustainability, supported by a rigorous ISO-certiﬁed Life Cycle Assessment (LCA) conducted in 2024.1 This assessment evaluated the environmental footprint of the product across its entire lifecycle—from raw material sourcing to manufacturing, distribution, use, and disposal. The eco-design approach has led to the below environmental gains, by optimising each step of Toujeo's product lifecycle:1

A key milestone in this journey is the transition to 100% renewable electricity across all insulin manufacturing facilities, reinforcing our commitment to sustainable healthcare delivery.1

<h2 style="text-align:center;">RePen Recycling Scheme</h2>
Sanofi is committed to reducing the environmental impact of diabetes care. The RePen recycling scheme allows patients to return used insulin pens for responsible disposal and recycling.
For more information about the RePen recycling programme and to find your nearest participating location, please visit <a href="https://www.mysanofiinsulin.co.uk/repen/">mysanofiinsulin.co.uk/repen</a>

<h2>Dedicated Support</h2>
Our UK-based customer care team is available to provide support and information regarding our insulin products via <a href="mailto:sanoficares@sanofi.com" target="_blank">sanoficares@sanofi.com</a>.
Our team can provide information on product availability, storage recommendations, and address general enquiries about our insulin products.

Toujeo®

Lantus®

Reference:

Frequently Asked Questions (FAQs)

MAT-XU-2504557 (v4.0) | Date of preparation: July 2026

Sanofi's Commitment to Diabetes with Insulin Supply in the UK

<h2>What is Atopic Dermatitis</h2>
Atopic dermatitis (AD) is a chronic disease driven by persistent underlying inflammation even in nonlesional or normal looking skin 1-3&nbsp;
<ul>
 <li>Atopic dermatitis is an immunological disease where the immune system causes more inflammation than normal</li>
 <li>The overactive immune system under the surface may lead to increased inflammation on the surface and is a contributing factor to the itchy patches on the skin</li>
 <li>Moderate-to-severe AD in adults is a chronic, debilitating inflammatory condition that requires long-term control 1,4</li>
</ul>

<h2>Challenges of treating Atopic Dermatitis</h2>
Atopic dermatitis (AD) is a chronic disease driven by persistent underlying Type 2 inflammation 1-3&nbsp;
Even skin that appears non-lesional on the surface is clearly distinct from normal skin:1-3&nbsp;

Non-lesional skin in AD has been shown to have cutaneous expansion of T cells and abnormalities that are largely similar to lesional AD skin. This highlights the importance of early identification and treatment of patients with this condition.&nbsp;

SPECIALTY-CARE

DUPIXENT

IMMUNOLOGY

ATOPIC-DERMATITIS

DERMATOLOGY

Tool to identify an uncontrolled AD patient&nbsp;

<ul>
 <li>In the UK, ciclosporin is the only conventional systemic immunosuppressant approved for the management of severe AD in adults5.&nbsp;Other systemic immunosuppressants are used off-label, despite limited evidence supporting their efficacy and safety6-8 </li>
 <li>Systemic immunosuppressants exert broad suppression of the immune system, while immunomodulators target specific immune pathways/cell types, thereby reducing off-target effects9 </li>
 <li>Broad-acting immunosuppressants are associated with a range of toxicities and side effects that limit their long-term use and require routine laboratory monitoring to minimise the risks 6,7,10,11</li>
</ul>

AD experts* proposed four types of treatment failure which patients with AD may experience despite appropriate dose, duration and adherence to a therapeutic agent12:&nbsp;
<ol>
 <li>Inadequate clinical improvement12&nbsp;</li>
 <li>Failure to achieve stable long-terms disease control12</li>
 <li>Adverse events or poor tolerability with current treatment12</li>
 <li>Failure to relieve burden of disease† 12</li>
</ol>

*A steering committee that consisted of a multi-disciplinary group of AD experts, including 8 dermatologists, two allergists and a patient advocacy group representative. This group met to identify and prioritise a number of essential questions concerning the evaluation and management of moderate-to-severe AD in the era of biologic therapies&nbsp;
†Presence of ongoing impairment (e.g., pruritus, pain, loss of sleep, and poor quality of life) while on treatment

<h2>The Role of Type 2 Inflammation&nbsp;</h2>
Dysregulated signaling of IL-4 and IL-13—two key drivers of type 2 inflammation—plays an important role in the pathogenesis of AD&nbsp; 13-18&nbsp;
IL-4 is a key upstream modulator of Th2 response, promoting a positive feedback loop that contributes to dysregulated secretion of IL-4, IL-13, and IL-31 #&nbsp;

IL-4 and IL-13 have overlapping roles in Type 2 inflammation:

<h3>Management approaches in AD should address the persistent underlying Type 2 inflammation&nbsp;&nbsp;</h3>
<ul>
 <li>Three types of immune response play a natural protective role against different pathogens, the Type 2 immune response drives AD specifically 1-3&nbsp;</li>
 <li>Broad spectrum immunosuppressants do not specifically inhibit Type 2 inflammatory pathway&nbsp;19-21&nbsp;</li>
 <li>Non-specific mechanisms may result in unwanted side effects and the need for lab monitoring, limiting traditional systemic treatments as long-term therapeutic options 1,19-24&nbsp;</li>
</ul>

<h3>DUPIXENT directly targets the underlying type 2 inflammation involved in AD.</h3>

Read to learn more about Atopic Dermatitis and its underlying causes 

DUPIXENT (dupilumab) Prescribing Information UK

An Introduction to Atopic Dermatitis

A short animation for bone specialists, including orthopaedic and rheumatology, to support the diagnosis of Gaucher disease.&nbsp;

Gaucher Bone Diagnosis Support

RARE-DISEASE

GAUCHER

<h2>Programme for Injectable Therapies for People with Type 2 Diabetes</h2>

<h3>&nbsp;</h3>
To register your interest in PITstop contact your local representative, or use the form below to get in touch and find a representative in your area.
Registering does not guarantee a place on PITstop

DIABETES-NON-CORE

INSUMAN-PREMIX

INSUMAN-BASAL

SOLIQUA

AMARYL

DAPAGLIF-PLUS-XR

DAONIL

LANTUS

TOUJEO

INSULIN-LISPRO-SANOFI

INSUMAN-RAPID

LYXUMIA

DAPAGLIF

APIDRA

INSULIN-GLARGINE-U100-SANOFI

INSULIN-ASPART-SANOFI

An accredited virtual promotional training course held over 2.5 days that supports healthcare professionals who are managing people with Type 2 diabetes on more complex regimens, including GLP-1 and insulin initiation.

<h4>Programme summary</h4>
Expect a variety of different topics on devices, insulins and other injectable therapies including:
<ul>
 <li>Revision of diabetes oral medications</li>
 <li>GLP-1 agonists including initiation using a structured care pathway</li>
 <li>Detective work at review appointments focusing on injectables</li>
 <li>Insulin safety (self-directed learning)</li>
 <li>Working through the PITstop insulin pathway to assess for insulin, initiate an appropriate insulin regimen and support the patient for the first 6 months: a case study approach</li>
 <li>Dietary considerations and insulin, including minimising weight gain</li>
 <li>Embedding the learning and university accreditation</li>
</ul>

<h4>Who is this course suitable for?</h4>
GPs, Nurse Practitioners, Practice Nurses, Clinical Pharmacists and Physician Associates (who are working as part of a practice diabetes team), already experienced in providing a diabetes service. Only HCPs who are patient facing and have the ability to initiate and prescribe injectables post the course should apply.
New to post DSNs identified as requiring training at this level, may also be suitable for this course.
Delegates must have completed a diabetes course to foundation level or be able to provide evidence of self-directed learning, focusing on the oral diabetes medication pathway. &nbsp;Suitable courses include Pre-PITstop, Warwick Certificate in Diabetes or Bradford Diabetes Certificate. You will be required to evidence this within your application.

<h4>Interested?</h4>
If you are interested in attending a course, please use the form below to get in touch with the Sanofi Diabetes Team.

Delegates who do not meet the course suitability criteria will not be registered onto the programme or may be contacted for further information. &nbsp;You will receive notification from Sanofi within 1 month once you have submitted your application confirming if you have been allocated a place on the course.

<h3>2026 Course Dates</h3>
PLEASE NOTE: All 2026 courses are now full. If you wish to be added to a waitlist for 2027, please use the form above.
Find below the dates for the 2 and a half day courses, starting in 2026.

<figure class="table" style="width:100%;">
 <table style="border-color:hsl(0, 0%, 0%);border-style:solid;">
 <tbody>
 <tr>
 <td style="background-color:hsl(91, 20%, 86%);">
 <h4 style="text-align:center;">Day 1</h4>
 </td>
 <td style="background-color:hsl(91, 20%, 86%);">
 <h4 style="text-align:center;">Day 2</h4>
 </td>
 <td style="background-color:hsl(91, 20%, 86%);">
 <h4 style="text-align:center;">Day 3</h4>
 </td>
 </tr>
 <tr>
 <td colspan="3">First wave:</td>
 </tr>
 <tr>
 <td>
 Tuesday 17th March
 </td>
 <td>
 Wednesday 18th March
 </td>
 <td>
 Thursday 23rd April
 </td>
 </tr>
 <tr>
 <td colspan="3">Second wave:</td>
 </tr>
 <tr>
 <td>
 Thursday 21st May
 </td>
 <td>
 Friday 22nd May
 </td>
 <td>
 Friday 3rd July
 </td>
 </tr>
 <tr>
 <td colspan="3">Third wave:</td>
 </tr>
 <tr>
 <td>
 Tuesday 30th June
 </td>
 <td>
 Wednesday 1st July
 </td>
 <td>
 Tuesday 8th September
 </td>
 </tr>
 <tr>
 <td colspan="3">Fourth wave:</td>
 </tr>
 <tr>
 <td>
 Tuesday 13th October
 </td>
 <td>
 Wednesday 14th October
 </td>
 <td>
 Wednesday 11th November
 </td>
 </tr>
 </tbody>
 </table>
</figure>

This educational programme is organised and funded by Sanofi. The PITstop for Diabetes course content has been independently developed and will be delivered by PITstop for Diabetes on behalf of Sanofi. Sanofi have had no input or involvement in the creation of these materials but has reviewed the content to ensure compliance with the ABPI code of practice. Adverse event reporting and prescribing information is available at the meetings.

If you would like to contact us further to discuss your place please either reach out to your local representative or email us at <a href="mailto:SanofiPITstop@sanofi.com">SanofiPITstop@sanofi.com</a>

Community Diabetes Specialist Nurse

Heidi Irons

Get in touch with the Diabetes Team

This course is intended for NHS Healthcare professionals only.

Pitstop | Diabetes

<a href="https://pro.campus.sanofi/dam/jcr:2a02177b-5764-4cb8-98b6-34b9445e0571/Toujeo%20PI.pdf" target="_blank">Toujeo (insulin glargine 300U/mL) Prescribing Information</a>
<a href="https://pro.campus.sanofi/dam/jcr:97e86e26-07fe-49e8-b6f3-31758c4a1495/Lantus%20PI.pdf">Lantus (insulin glargine 100U/mL) Prescribing Information</a>

<h3>Want to rewatch the webinar? Jump to the <a href="https://pro.campus.sanofi/uk/events/expert-insights?internal=true#recording" target="_self">recording here</a></h3>
Levemir is being discontinued with stock expected to run out by end of 2026. As the only basal insulin licensed for twice-daily use, there's no direct alternative — a planned, proactive approach to switching is essential.¹
Sanofi have been supporting the switch efforts by running webinars and talks at Diabetes UK 2026. We were joined by three leading speakers, each with hands-on experience in managing insulin switches:

You can find the key takeaways and speaker insights from these events below:
<h3>
 
 What do I need to consider before the switch is made?
</h3>

What does the guidance say?

Which insulin should I switch to?

How do I optimise the treatment regimen?

INTEGRATED-DIABETES-CARE

<h3>What clinical considerations need to be made when making the switch?</h3>
The ABCD PCDOS guidance states that “when switching between insulins, there can be differences between absorption, potency, and action profile, therefore consider reducing doses by 10-20% to avoid the initial risk of hypoglycaemia.” ¹
Close monitoring is required:²,³ where possible, people with diabetes should be encouraged to self-adjust insulin doses according to their blood glucose concentrations after switching to alternative insulins whilst awaiting a further review.¹
Read the guidance below to see specific guidance and case studies for patients with Type 1 and Type 2 Diabetes

Switching in Type 1

Switching in Type 2

<h3>What were the highlights?</h3>
Watch the reel below for the standout moments from each speaker and the Q&amp;A.

Expert Insights: Managing upcoming Insulin Discontinuations

<h3>Looking for more support?</h3>

Therapeutic Areas

Latest Articles

Sanofi's Commitment to Diabetes with Insulin Supply in the UK

An Introduction to Atopic Dermatitis

Gaucher Bone Diagnosis Support

Latest Resources

Dupixent (dupilumab) Resources

Formulary & Service Support

Praluent® (alirocumab) - Comprehensive Support for the Praluent® Patient

Latest Tools

Numerical Rating Scale (NRS)

Atopic Dermatitis Control Tool (ADCT)

Asthma AAC Tool

Latest Events

Pitstop | Diabetes

Expert Insights: Managing upcoming Insulin Discontinuations

Latest Education

Patient Case Study Presentations - EBMT 2026

UK InTEN GvHD Forum - Skin GvHD Session

UK InTEN GvHD Forum - Lung GvHD Session